Sugi Predict

Sugi Predict / Compounds / SCHEMBL6340824

SCHEMBL6340824

SCHEMBL6340824

C[Si](C)(C)CCOC(=O)N1CCNCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TSHR P16473 1/20 0.40
▸ CA2 P00918 2/20 0.37
▸ CA12 O43570 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ CHKA P35790 1/20 0.36
▸ CHRNB2 P17787 1/20 0.35
▸ CHRNA3 P32297 1/20 0.35
▸ CHRNA4 P43681 1/20 0.35
▸ CHRNB3 Q05901 1/20 0.35
▸ CHRNA6 Q15825 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ HTT P42858 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29535838 0.84 POLB (0.45) POLBSMN1; SMN2LMNATSHRRECQL
SCHEMBL31129567 0.82 ITGB3 (0.38) POLBSMN1; SMN2LMNATSHRGAA
SCHEMBL6820687 0.82 POLB (0.44) POLBSMN1; SMN2LMNATSHRRECQL
SCHEMBL952311 0.80 POLB (0.49) POLBSMN1; SMN2LMNATSHRCA2
SCHEMBL6062384 0.79 GAA (0.41) POLBSMN1; SMN2LMNATSHRALDH1A1
SCHEMBL16599995 0.79 MEN1 (0.43) POLBSMN1; SMN2LMNATSHRCA2
SCHEMBL20240537 0.78 CA2 (0.42) POLBSMN1; SMN2LMNATSHRCA2
SCHEMBL22122716 0.78 CA2 (0.42) POLBSMN1; SMN2LMNATSHRCA2
SCHEMBL2038483 0.78 POLB (0.41) POLBSMN1; SMN2LMNATSHRRECQL
SCHEMBL1972696 0.78 POLB (0.41) POLBSMN1; SMN2LMNATSHRRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188092-A1 RIFAMYCIN ANALOGS THE PENN STATE RESEARCH FOUNDATION 2025-06-12 — — US disclosed
WO-2025049804-A2 AGENTS FOR THE TREATMENT OF NON-REPLICATING BACTERIA ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2025-03-06 — — WO disclosed
WO-2025019599-A2 BIFUNCTIONAL KINASE BINDING COMPOUNDS AND USES THEREOF PHOTYS THERAPEUTICS, INC. (US) 2025-01-23 — — WO disclosed
WO-2022159491-A1 RIFAMYCIN ANALOGS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2022-07-28 — — WO disclosed
WO-2012071469-A2 HISTONE DEMETHYLASE INHIBITORS AND USES THEREOF FOR TREATMENT O F CANCER NEVADA CANCER INSTITUTE (US) 2012-05-31 — — WO disclosed
US-6893815-B1 Nucleobase heterocyclic combinatorialization ISIS PHARMACEUTICALS, INC. (US) 2005-05-17 — — US disclosed
US-20020009748-A1 NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION ISIS PHARMACEUTICALS, INC. 2002-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020009748-A1 NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION PNP, ATIC, DPYD POLB 330/4885SMN1; SMN2 894/4885LMNA 1758/4885
US-20250188092-A1 RIFAMYCIN ANALOGS CYP3A4, CYP4B1, CYP2C9 POLB 187/4885SMN1; SMN2 4864/4885LMNA 3080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.